Korean J Psychopharmacol.  2012 Oct;23(4):131-135.

Alzheimer's Disease: Clinical Trials and Future Perspectives

• Lee KS
• Suh HS

Abstract

Alzheimer's disease is increasingly common in elderly population with a large socioeconomic burden. Current available drugs for Alzheimer's disease are acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist. Much effort is directed towards not just symptomatic treatments but disease-modifying treatments. Several drugs with differing targets and mechanisms of action are under development for the treatment of Alzheimer's disease. Phase III trials of dimebon, Ginkgo biloba, non-steroidal anti-inflammatory drugs, phenserine, statins, semagacestat, tarenflurbil, tramiprosate, valproate, xaliproden have been completed without demonstrating adequate efficacy. Encouraging results would be expected from ongoing phase III trials of bapineuzumab and solanezumab. The clinical trials for the disease-modifying treatment of Alzheimer's disease have resulted in both promise and disappointment.

Keyword

Alzheimer's disease; Clinical trial; Bapineuzumab; Solanezumab

MeSH Terms

Aged
Alanine
Alzheimer Disease
Antibodies, Monoclonal, Humanized
Azepines
Cholinesterase Inhibitors
Flurbiprofen
Ginkgo biloba
Humans
Indoles
N-Methylaspartate
Naphthalenes
Physostigmine
Pyridines
Taurine
Valproic Acid
Alanine
Antibodies, Monoclonal, Humanized
Azepines
Cholinesterase Inhibitors
Flurbiprofen
Indoles
N-Methylaspartate
Naphthalenes
Physostigmine
Pyridines
Taurine
Valproic Acid